Homing to solid cancers: A vascular checkpoint in adoptive cell therapy using CAR T-cells

Biochemical Society Transactions

Volumn 44, Issue 2, 2016, Pages 377-385

  Ager, Ann ^a   Watson, H Angharad ^a   Wehenkel, Sophie C ^a   Mohammed, Rebar N ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Chemokine receptors; Endothelial cell anergy; Extravasation; High endothelial venules; Homing; Integrins; Selectins; Tumour blood vessels; Tumouricidal T lymphocytes; Vessel normalization

Indexed keywords

CHIMERIC PROTEIN; INTERLEUKIN 33; RECEPTOR ANTIBODY;

ANGIOGENESIS; ANIMAL MODEL; ANTIANGIOGENIC THERAPY; BLOOD FLOW; BLOOD VESSEL; BLOOD VESSEL WALL; CANCER PATIENT; CANCER THERAPY; CANCER TISSUE; CD8+ T LYMPHOCYTE; CELL THERAPY; CLINICAL STUDY; EXPERIMENTAL ANIMAL; EXPERIMENTAL STUDY; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; T LYMPHOCYTE; VASCULAR TUMOR; ADOPTIVE TRANSFER; ANIMAL; IMMUNOLOGY; MOUSE; NEOPLASMS;

ADOPTIVE TRANSFER; ANIMALS; HUMANS; MICE; NEOPLASMS; T-LYMPHOCYTES;

EID: 85009841550     PISSN: 03005127     EISSN: 14708752     Source Type: Journal    
DOI: 10.1042/BST20150254     Document Type: Review

References (60)

1. Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pages, C., Tosolini, M., Camus, M., Berger, A., Wind, P. et al. (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960-1964
2. Fridman, W.H., Pages, F., Sautes-Fridman, C. and Galon, J. (2012) The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 12, 298-306
3. Martinet, L., Garrido, I., Filleron, T., Le Guellec, S., Bellard, E., Fournie, J.J., Rochaix, P. and Girard, J.P. (2011) Human solid tumors contain high endothelial venules: association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer. Cancer Res. 71, 5678-5687
4. Martinet, L., Le Guellec, S., Filleron, T., Lamant, L., Meyer, N., Rochaix, P., Garrido, I. and Girard, J.P. (2012) High endothelial venules (HEVs) in human melanoma lesions: major gateways for tumor-infiltrating lymphocytes. Oncoimmunology 1, 829-839
5. Dudley, M.E., Wunderlich, J.R., Robbins, P.F., Yang, J.C., Hwu, P., Schwartzentruber, D.J., Topalian, S.L., Sherry, R., Restifo, N.P., Hubicki, A.M. et al. (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298, 850-854
6. Morgan, R.A., Dudley, M.E., Wunderlich, J.R., Hughes, M.S., Yang, J.C., Sherry, R.M., Royal, R.E., Topalian, S.L., Kammula, U.S., Restifo, N.P. et al. (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126-129
7. Kalos, M., Levine, B.L., Porter, D.L., Katz, S., Grupp, S.A., Bagg, A. and June, C.H. (2011) T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3, 95ra73
8. Brentjens, R.J., Riviere, I., Park, J.H., Davila, M.L., Wang, X., Stefanski, J., Taylor, C., Yeh, R., Bartido, S., Borquez-Ojeda, O. et al. (2011) Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118, 4817-4828
9. Brentjens, R.J., Davila, M.L., Riviere, I., Park, J., Wang, X., Cowell, L.G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M. et al. (2013) CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 5, 177ra138
10. Luster, A.D., Alon, R. and von Andrian, U.H. (2005) Immune cell migration in inflammation: present and future therapeutic targets. Nat. Immunol. 6, 1182-1190
11. Masopust, D. and Schenkel, J.M. (2013) The integration of T cell migration, differentiation and function. Nat. Rev. Immunol. 13, 309-320
12. Reinhardt, R.L., Khoruts, A., Merica, R., Zell, T. and Jenkins, M.K. (2001) Visualizing the generation of memory CD4 T cells in the whole body. Nature 410, 101-105
13. Agrewala, J.N., Brown, D.M., Lepak, N.M., Duso, D., Huston, G. and Swain, S.L. (2007) Unique ability of activated CD4+ T cells but not rested effectors to migrate to non-lymphoid sites in the absence of inflammation. J. Biol. Chem. 282, 6106-6115
14. Schenkel, J.M. and Masopust, D. (2014) Tissue-resident memory T cells. Immunity 41, 886-897
15. Masopust, D., Vezys, V., Marzo, A.L. and Lefrancois, L. (2001) Preferential localization of effector memory cells in nonlymphoid tissue. Science 291, 2413-2417
16. Masopust, D., Vezys, V., Usherwood, E.J., Cauley, L.S., Olson, S., Marzo, A.L., Ward, R.L., Woodland, D.L. and Lefrancois, L. (2004) Activated primary and memory CD8 T cells migrate to nonlymphoid tissues regardless of site of activation or tissue of origin. J. Immunol. 172, 4875-4882
17. Yang, S., Ji, Y., Gattinoni, L., Zhang, L., Yu, Z., Restifo, N.P., Rosenberg, S.A. and Morgan, R.A. (2013) Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails. Cancer Immunol. Immunother 62, 727-736
18. Mionnet, C., Sanos, S.L., Mondor, I., Jorquera, A., Laugier, J.P., Germain, R.N. and Bajenoff, M. (2011) High endothelial venules as traffic control points maintaining lymphocyte population homeostasis in lymph nodes. Blood 118, 6115-6122
19. Ager, A. and May, M.J. (2015) Understanding high endothelial venules: lessons for cancer immunology. Oncoimmunology 4, e1008791
20. Walch, J.M., Zeng, Q., Li, Q., Oberbarnscheidt, M.H., Hoffman, R.A., Williams, A.L., Rothstein, D.M., Shlomchik, W.D., Kim, J.V., Camirand, G. and Lakkis, F.G. (2013) Cognate antigen directs CD8+ T cell migration to vascularized transplants. J. Clin. Invest. 123, 2663-2671
21. Marelli-Berg, F.M., James, M.J., Dangerfield, J., Dyson, J., Millrain, M., Scott, D., Simpson, E., Nourshargh, S. and Lechler, R.I. (2004) Cognate recognition of the endothelium induces HY-specific CD8+ T-lymphocyte transendothelial migration (diapedesis) in vivo. Blood 103, 3111-3116
22. Fisher, D.T., Chen, Q., Skitzki, J.J., Muhitch, J.B., Zhou, L., Appenheimer, M.M., Vardam, T.D., Weis, E.L., Passanese, J., Wang, W.C. et al. (2011) IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells. J. Clin. Invest. 121, 3846-3859
23. Sharma, R.K., Chheda, Z., Jala, V.R. and Haribabu, B. (2013) Expression of leukotriene B(4) receptor-1 on CD8(+) T cells is required for their migration into tumors to elicit effective antitumor immunity. J. Immunol. 191, 3462-3470
24. Mikucki, M.E., Fisher, D.T., Matsuzaki, J., Skitzki, J.J., Gaulin, N.B., Muhitch, J.B., Ku, A.W., Frelinger, J.G., Odunsi, K., Gajewski, T.F. et al. (2015) Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints. Nat. Commun. 6, 7458
25. Peske, J.D., Thompson, E.D., Gemta, L., Baylis, R.A., Fu, Y.X. and Engelhard, V.H. (2015) Effector lymphocyte-induced lymph node-like vasculature enables naive T-cell entry into tumours and enhanced anti-tumour immunity. Nat. Commun. 6, 7114
26. Craddock, J.A., Lu, A., Bear, A., Pule, M., Brenner, M.K., Rooney, C.M. and Foster, A.E. (2010) Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J. Immunother. 33, 780-788
27. Moon, E.K., Carpenito, C., Sun, J., Wang, L.C., Kapoor, V., Predina, J., Powell, Jr, D.J., Riley, J.L., June, C.H. and Albelda, S.M. (2011) Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin. Cancer Res. 17, 4719-4730
28. Fukumura, D., Salehi, H.A., Witwer, B., Tuma, R.F., Melder, R.J. and Jain, R.K. (1995) Tumor necrosis factor alpha-induced leukocyte adhesion in normal and tumor vessels: effect of tumor type, transplantation site, and host strain. Cancer Res. 55, 4824-4829
29. Bessa, X., Elizalde, J.I., Mitjans, F., Pinol, V., Miquel, R., Panes, J., Piulats, J., Pique, J.M. and Castells, A. (2002) Leukocyte recruitment in colon cancer: role of cell adhesion molecules, nitric oxide, and transforming growth factor beta1. Gastroenterology 122, 1122-1132
30. Joyce, J.A. and Fearon, D.T. (2015) T cell exclusion, immune privilege, and the tumor microenvironment. Science 348, 74-80
31. Buckanovich, R.J., Facciabene, A., Kim, S., Benencia, F., Sasaroli, D., Balint, K., Katsaros, D., O'Brien-Jenkins, A., Gimotty, P.A. and Coukos, G. (2008) Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat. Med. 14, 28-36
32. Motz, G.T., Santoro, S.P., Wang, L.P., Garrabrant, T., Lastra, R.R., Hagemann, I.S., Lal, P., Feldman, M.D., Benencia, F. and Coukos, G. (2014) Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat. Med. 20, 607-615
33. Dirkx, A.E., oude Egbrink, M.G., Castermans, K., van der Schaft, D.W., Thijssen, V.L., Dings, R.P., Kwee, L., Mayo, K.H., Wagstaff, J., Bouma-ter Steege, J.C. and Griffioen, A.W. (2006) Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J. 20, 621-630
34. Kuzu, I., Bicknell, R., Fletcher, C.D. and Gatter, K.C. (1993) Expression of adhesion molecules on the endothelium of normal tissue vessels and vascular tumors. Lab. Invest. 69, 322-328
35. Mrass, P., Takano, H., Ng, L.G., Daxini, S., Lasaro, M.O., Iparraguirre, A., Cavanagh, L.L., von Andrian, U.H., Ertl, H.C., Haydon, P.G. and Weninger, W. (2006) Random migration precedes stable target cell interactions of tumor-infiltrating T cells. J. Exp. Med. 203, 2749-2761
36. Boissonnas, A., Fetler, L., Zeelenberg, I.S., Hugues, S. and Amigorena, S. (2007) In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor. J. Exp. Med. 204, 345-356
37. Sampson, J.H., Choi, B.D., Sanchez-Perez, L., Suryadevara, C.M., Snyder, D.J., Flores, C.T., Schmittling, R.J., Nair, S.K., Reap, E.A., Norberg, P.K. et al. (2014) EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. Clin. Cancer Res. 20, 972-984
38. Gattinoni, L., Klebanoff, C.A., Palmer, D.C., Wrzesinski, C., Kerstann, K., Yu, Z., Finkelstein, S.E., Theoret, M.R., Rosenberg, S.A. and Restifo, N.P. (2005) Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J. Clin. Invest. 115, 1616-1626
39. Pockaj, B.A., Sherry, R.M., Wei, J.P., Yannelli, J.R., Carter, C.S., Leitman, S.F., Carasquillo, J.A., Steinberg, S.M., Rosenberg, S.A. and Yang, J.C. (1994) Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response. Cancer 73, 1731-1737
40. Kershaw, M.H., Westwood, J.A., Parker, L.L., Wang, G., Eshhar, Z., Mavroukakis, S.A., White, D.E., Wunderlich, J.R., Canevari, S., Rogers-Freezer, L. et al. (2006) A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12, 6106-6115
41. Carriere, V., Colisson, R., Jiguet-Jiglaire, C., Bellard, E., Bouche, G., Al Saati, T., Amalric, F., Girard, J.P. and M'Rini, C. (2005) Cancer cells regulate lymphocyte recruitment and leukocyte-endothelium interactions in the tumor-draining lymph node. Cancer Res. 65, 11639-11648
42. Palmer, D.C., Balasubramaniam, S., Hanada, K., Wrzesinski, C., Yu, Z., Farid, S., Theoret, M.R., Hwang, L.N., Klebanoff, C.A., Gattinoni, L. et al. (2004) Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction. J. Immunol. 173, 7209-7216
43. Dudley, M.E., Yang, J.C., Sherry, R., Hughes, M.S., Royal, R., Kammula, U., Robbins, P.F., Huang, J., Citrin, D.E., Leitman, S.F. et al. (2008) Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26, 5233-5239
44. John, L.B., Devaud, C., Duong, C.P., Yong, C.S., Beavis, P.A., Haynes, N.M., Chow, M.T., Smyth, M.J., Kershaw, M.H. and Darcy, P.K. (2013) Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin. Cancer Res. 19, 5636-5646
45. Peng, W., Liu, C., Xu, C., Lou, Y., Chen, J., Yang, Y., Yagita, H., Overwijk, W.W., Lizee, G., Radvanyi, L. and Hwu, P. (2012) PD-1 blockade enhances T-cell migration to tumors by elevating IFN-gamma inducible chemokines. Cancer Res. 72, 5209-5218
46. Travis, L.B., Curtis, R.E., Glimelius, B., Holowaty, E.J., Van Leeuwen, F.E., Lynch, C.F., Hagenbeek, A., Stovall, M., Banks, P.M., Adami, J. et al. (1995) Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J. Natl. Cancer Inst. 87, 524-530
47. Folkman, J. (1971) Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182-1186
48. Facciabene, A., Peng, X., Hagemann, I.S., Balint, K., Barchetti, A., Wang, L.P., Gimotty, P.A., Gilks, C.B., Lal, P., Zhang, L. and Coukos, G. (2011) Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 475, 226-230
49. Huang, Y., Yuan, J., Righi, E., Kamoun, W.S., Ancukiewicz, M., Nezivar, J., Santosuosso, M., Martin, J.D., Martin, M.R., Vianello, F. et al. (2012) Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc. Natl. Acad. Sci. U.S.A. 109, 17561-17566
50. Hamzah, J., Jugold, M., Kiessling, F., Rigby, P., Manzur, M., Marti, H.H., Rabie, T., Kaden, S., Grone, H.J., Hammerling, G.J. et al. (2008) Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 453, 410-414
51. Shrimali, R.K., Yu, Z., Theoret, M.R., Chinnasamy, D., Restifo, N.P. and Rosenberg, S.A. (2010) Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res. 70, 6171-6180
52. Li, X., Kostareli, E., Suffner, J., Garbi, N. and Hammerling, G.J. (2010) Efficient Treg depletion induces T-cell infiltration and rejection of large tumors. Eur. J. Immunol. 40, 3325-3335
53. Johansson, A., Hamzah, J., Payne, C.J. and Ganss, R. (2012) Tumor-targeted TNFalpha stabilizes tumor vessels and enhances active immunotherapy. Proc. Natl. Acad. Sci. U.S.A. 109, 7841-7846
54. Calcinotto, A., Grioni, M., Jachetti, E., Curnis, F., Mondino, A., Parmiani, G., Corti, A. and Bellone, M. (2012) Targeting TNF-alpha to neoangiogenic vessels enhances lymphocyte infiltration in tumors and increases the therapeutic potential of immunotherapy. J. Immunol. 188, 2687-2694
55. Carretero, R., Sektioglu, I.M., Garbi, N., Salgado, O.C., Beckhove, P. and Hammerling, G.J. (2015) Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. Nat. Immunol. 16, 609-617
56. Ganss, R., Ryschich, E., Klar, E., Arnold, B. and Hammerling, G.J. (2002) Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res. 62, 1462-1470
57. Garbi, N., Arnold, B., Gordon, S., Hammerling, G.J. and Ganss, R. (2004) CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction. J. Immunol. 172, 5861-5869
58. Hindley, J.P., Jones, E., Smart, K., Bridgeman, H., Lauder, S.N., Ondondo, B., Cutting, S., Ladell, K., Wynn, K.K., Withers, D. et al. (2012) T-cell trafficking facilitated by high endothelial venules is required for tumor control after regulatory T-cell depletion. Cancer Res. 72, 5473-5482
59. Yu, P., Lee, Y., Liu, W., Chin, R.K., Wang, J., Wang, Y., Schietinger, A., Philip, M., Schreiber, H. and Fu, Y.X. (2004) Priming of naive T cells inside tumors leads to eradication of established tumors. Nat. Immunol. 5, 141-149
60. Onder, L., Danuser, R., Scandella, E., Firner, S., Chai, Q., Hehlgans, T., Stein, J.V. and Ludewig, B. (2013) Endothelial cell-specific lymphotoxin-beta receptor signaling is critical for lymph node and high endothelial venule formation. J. Exp. Med. 210, 465-473